KalVista Pharmaceuticals Inc KALV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
-
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
-
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
-
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
-
KalVista Appoints Brian Piekos as Chief Financial Officer
-
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
-
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
Trading Information
- Previous Close Price
- $11.54
- Day Range
- $11.14–11.82
- 52-Week Range
- $7.21–16.88
- Bid/Ask
- $9.00 / $11.79
- Market Cap
- $490.93 Mil
- Volume/Avg
- 448,251 / 384,556
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 150
- Website
- https://www.kalvista.com
Comparables
Valuation
|
Metric
|
KALV
|
CTNM
|
RCKT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.83 | 2.01 | 3.88 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
KALV
CTNM
RCKT
Financial Strength
|
Metric
|
KALV
|
CTNM
|
RCKT
|
|---|---|---|---|
Quick Ratio | 8.32 | 58.48 | 7.42 |
Current Ratio | 8.55 | 58.92 | 7.79 |
Interest Coverage | — | — | −143.43 |
Quick Ratio
KALV
CTNM
RCKT
Profitability
|
Metric
|
KALV
|
CTNM
|
RCKT
|
|---|---|---|---|
Return on Assets (Normalized) | −71.09% | −18.15% | −41.09% |
Return on Equity (Normalized) | −83.59% | −871.68% | −46.72% |
Return on Invested Capital (Normalized) | −82.62% | −892.99% | −47.69% |
Return on Assets
KALV
CTNM
RCKT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ppjcymvwxw | Qpjx | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kdjqzmq | Xqfypy | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lddfmscx | Cplcfx | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cxblmwc | Tbqndb | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Cpzkthy | Lmjxl | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Bblnxgjv | Fcwl | $29.2 Bil | |||
| Moderna Inc
MRNA
| Rfqtjskmw | Mndd | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Kgjvdzz | Fqdcf | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yhsclnsv | Zdflq | $13.2 Bil | |||
| Incyte Corp
INCY
| Tcdzlxm | Xrpsnsv | $13.0 Bil |
United States